产品中心
- 产品简介
- 使用说明
- 相关产品
- 参考文献
- 购买咨询
Catalog# CH73 Source E. coli Description Recombinant Human KGF is produced with our E. coli expression system. The target protein is expressed with sequence (Cys32-Thr194) of Human KGF. Names Fibroblast growth factor 7,FGF-7,Heparin-binding growth factor 7,HBGF-7,Keratinocyte growth factor,FGF7,KGF Accession # P21781 Formulation Lyophilized from a 0.2 μm filtered solution of 20mM PB,pH8.0,l50mM NaCl Shipping The product is shipped at ambient temperature. Reconstitution Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in 1X PBS.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.Storage Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.Purity Greater than 95% as determined by SEC-HPLC and reducing SDS-PAGE. Endotoxin Less than 0.1 ng/µg (1 IEU/µg). Amino Acid Sequence CNDMTPEQMATNVNCSSPERHTRSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYN IMEIRTVAVGIVAIKGVESEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGG EMFVALNQKGIPVRGKKTKKEQKTAHFLPMAITBackground Fibroblast growth factor 7 (FGF7) is a secreted protein which is mainly located in epithelial cells and belongs to the heparin-binding growth factors family. FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. FGF7 is a potent epithelial cell-specific growth factor, whose mitogenic activity is predominantly exhibited in keratinocytes but not in fibroblasts and endothelial cells. It is possible major paracrine effector of normal epithelial cell proliferation. References Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas